Diverse TCR-T therapies
Anocca has established a pipeline of TCRs against multiple antigen classes, including targets that are shared amongst tumours, against specific genetic mutations that drive cancer, and against viruses that cause cancer. These TCR assets pipelines address a range of HLA restrictions, expanding the reach of TCR-modified T-cell (TCR-T) therapies to many more patients. Anocca is also deploying our technology to systematically isolate TCRs for neoantigens identified from tumours on an entirely individualised basis.
in EBV transformed cancers
Neoantigens in Patient HLAs
Cell-based discovery of tumour and viral antigens
Anocca deploys antigen technologies to discover and validate new cancer antigens, down to the level of individual mutations in specific individual tumours. Our discovery is focused on several target classes including shared tumour antigens, cancer driver mutations and viral proteins. This work is conducted on a library of HLA genes that address a majority of the world-wide population. Anocca is also deploying a technology pipeline to functionally validate neoantigens in tumours that are identified by next generation sequencing on an individualised basis. These pipelines aim to radically expand the access to transformative next-generation of immunotherapies, which include TCR-modified T-cell therapies, but also advanced vaccination approaches.
Moving beyond oncology
Anocca’s platform has been designed to be re-usable for indications beyond oncology, and in distinct biopharmaceutical applications. In particular, the platform can be deployed in design and deployment of advanced vaccination approaches for personalised tumour vaccines, for prophylactic vaccines for a wide range of pathogens, and for tolerisation of autoimmunity. Anocca has active research programs to deliver novel approaches in these areas, in addition to sophisticated immunosurveillance toolsets for patient management and stratification.